Ashley Yeo
Ashley Yeo is attached to the medtech titles within Informa’s Pharma intelligence division.
As Health Care editor on In Vivo (monthly hardcopy and online daily services), he writes and commissions news and feature material to meet the strategic business and market access information needs of senior players and device makers as they move innovations into the global medtech market place.
As part of the Principal Analyst team, he also contributes news delivery and insight needs across the group’s other medtech titles in the field of market access (global regulatory, reimbursement, policy changes). Key areas of focus are Germany, the UK and global themes, and EU and other outside global regulatory insight.
A linguist by training, he joined what was later to become Informa in mid-1988 as a French and German news reporter (with some other European languages also in the mix), and has been editor of three of the group’s titles (including Clinica) over a 14-year-period.
These duties are combined with supporting the growing Ask The Analyst service. He says: “This helps us as a group keep a close relationship with long-term and potential subscribers in a sector where insight and knowledge are key to our clients’ commercial success.”
Latest From Ashley Yeo
Olympus Medical Follows The Patient Pathway In New Strategic Plan
Having divested non-medical imaging a year ago, Olympus Corp is putting its foot to the floor in refocusing on its medical portfolio. It has set global ambitions of strengthening its coverage of unmet needs and of playing a major role in reshaping health care delivery.
Olympus Medical Follows The Patient Pathway In New Strategic Plan
Having divested non-medical imaging a year ago, Olympus Corp is putting its foot to the floor in refocusing on its medical portfolio. It has set global ambitions of strengthening its coverage of unmet needs and of playing a major role in reshaping health care delivery.
Cardio Industry Puts Weight Behind UK Call For National CVD Strategy
Better uptake of medtech in tackling cardiovascular disease can bring benefits across the entire pathway of care, say UK CVD companies, who are urging the government to improve levels of technology adoption.
Qiagen CFO Sees COVID Diagnostics Volatility Continuing In 2022
Qiagen’s doubled-down focus on PCR technologies in late 2019 proved to be fortuitous, but future growth will come from many other drivers, says CFO Roland Sackers.
Swiss Industry Makes Breakthrough For Local Market Device Labeling
Rules on the labeling needs for medtech products entering the Swiss market have been eased in what is seen by the local industry as a victory for pragmatism.
Innovation Trends Point To More Positives For Health Care Investors
At the end of a turbulent year for health care, COVID-19 is still dominating the thoughts of stakeholders, but CMS patent attorneys Jane Hollywood and Rob Stephen are encouraged by the innovation and investment trends that are making it an exciting time to be in the thick of the action.